HbA1c 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.1.3: 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD) 12 28 40 52.

Slides:

Advertisements

Similar presentations

Comparison of 4 Diets Dansinger, et al (2005). Comparison of Atkins, Ornish, Weight Watchers and Zone Diets for Weight Loss and Heart Disease Risk Reduction,

Advertisements

1 Hypertension 2002: An Overview. 2 Leading Risks For Death (World Health Organization 1995)

Age (years) Gender (Males), n (%) Dialysis duration (years) Hemoglobin (mg / dl) Pre dialysis SBP (mmHg) Pre dialysis DBP(mmHg) Post dialysis SBP (mmHg)

BELGIUM 27th !!! 1) HTA DE GRADE 3 = TOUJOURS RISQUE > ELEVE.

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.

Exercise the Medicine of Choice Reducing Cardiovascular Risk Dr. Lynn Panton Florida State University College of Human Sciences Department of Nutrition,

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

The Indian Polycap Study (TIPS). Lancet 2009 Mar 30 [Epub]

Farid Saad Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.

High level of low density lipoprotein cholesterol in adult children of patients with premature coronary heart disease: relation to own and parental characteristics.

Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.

HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal mg/dL Borderline High mg/dL High mg/dL.

Lesotho STEPS Survey 2012 Fact Sheet John Nkonyana Director Disease Control.

Pulmonary artery Pulmonary vein Left atrium Left Ventricle Aorta Vena Cava Right Atrium Right Ventricle.

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

Int J Clin Pract, December 2013, 67, 12,

CHAPTER 8: Blood Pressure Control and Dyslipidaemia in Patients on Dialysis S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 21 st.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Blood Pressure Systole Systolic pressure Diastole Diastolic pressure Pulse pressure mmHg.

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Category Sex Systolic BP (mmHg) Men (n=58) Women (n=106) P value

Lacto-ovo vegetarian group

YOUR HEALTH SCREENING RESULTS

Copyright © 2015 by the American Osteopathic Association.

From ESH 2016 | LB 3: Davide Agnoletti, MD

Raw data Log-transformed data Male age log age Female age log age

Baseline characteristics and effectiveness results

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

From ESH 2016 | POS 7D: Jan Rosa, MD

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Kidney Blood Press Res 2013;37: DOI: /

Neal B, et al. Diabetes Care 2015;38:403–411

ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.

Supplementary material

Copyright © 2012 American Medical Association. All rights reserved.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Empagliflozin Empagliflozin is a highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2) in the kidney Glucose reduction occurs by reducing.

End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

University of Alaska Win Utilization report 7/1/2011 to 6/30/2012

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Volume 93, Issue 1, Pages (January 2018)

Time point Difference in systolic BP (mm Hg) p

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

The Diabetes Cross-Disciplinary Index (DXDI).

© The Author(s) Published by Science and Education Publishing.

A B D C Total adiponectin (μg/ml ) Hb ( g / dl ) r = p = 0.003

Level of risk factor control in the overall sample and by gender

Influence of possible intermediary variables on PR interval mean difference (95% CI) between HIV-infected (ART-naïve or ART-exposed) children and healthy.

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Flow of Patients Through Trial

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Obesity Eppie Habashi.

RECORD Study: Enrollment and Outcomes

Characteristics of included studies

VK2809 in NAFLD: a phase 2 study

Influence of possible intermediary variables on QTc interval mean difference (95% CI) between HIV-infected (ART-naïve or ART-exposed) children and healthy.

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Change in markers of glycometabolism and cardiovascular risk profile.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Effect of empagliflozin on efficacy parameters at week 18.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

© The Author(s) Published by Science and Education Publishing.

Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.

Presentation transcript:

HbA1c 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.1.3: 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD) 12 28 40 52 66 80 94 108 122 136 150 164 178 192 206 Placebo 2294 2272 2188 2133 2113 2063 2008 1967 1741 1456 1241 1109 962 705 420 151 Empagliflozin 10 mg 2296 2272 2218 2150 2155 2108 2072 2058 1805 1520 1297 1164 1006 749 488 170 Empagliflozin 25 mg 2296 2280 2212 2152 2150 2115 2080 2044 1842 1540 1327 1190 1043 795 498 195 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

Weight Placebo Empagliflozin 10 mg Empagliflozin 25 mg 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.3.3: 1 Weight (kg) change from baseline MMRM results over time − treated set (OC−AD) 12 28 52 108 164 220 Placebo 2285 1915 2215 2138 1598 1239 425 Empagliflozin 10 mg 2290 1893 2238 2174 1673 1298 483 Empagliflozin 25 mg 2283 1891 2226 2178 1678 1335 489 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

Waist circumference Placebo Empagliflozin 10 mg Empagliflozin 25 mg 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.4.3: 1 Waist circumference (cm) change from baseline MMRM results over time − treated set (OC−AD) 12 28 52 108 164 220 Placebo 2259 1869 2183 2110 1562 1220 418 Empagliflozin 10 mg 2272 1836 2219 2155 1644 1285 475 Empagliflozin 25 mg 2273 1857 2209 2157 1648 1329 486 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

Systolic blood pressure Placebo Empagliflozin 25 mg Empagliflozin 10 mg 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.5.3: 1 SBP (mmHg) change from baseline MMRM results over time − treated set (OC−AD) 16 28 40 52 66 80 94 108 122 136 150 164 178 192 206 Placebo 2322 2235 2203 2161 2133 2073 2024 1974 1771 1492 1274 1126 981 735 450 171 Empagliflozin 10 mg 2322 2250 2235 2193 2174 2125 2095 2072 1853 1556 1327 1189 1034 790 518 199 Empagliflozin 25 mg 2323 2247 2221 2197 2169 2129 2102 2066 1878 1571 1351 1212 1070 842 528 216 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

Diastolic blood pressure Placebo Empagliflozin 25 mg Empagliflozin 10 mg 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.6.3: 1 DBP (mmHg) change from baseline MMRM results over time − treated set (OC−AD) 16 28 40 52 66 80 94 108 122 136 150 164 178 192 206 Placebo 2322 2235 2203 2161 2133 2073 2024 1974 1771 1492 1274 1126 981 735 450 171 Empagliflozin 10 mg 2322 2250 2235 2193 2174 2125 2095 2072 1853 1556 1327 1189 1034 790 518 199 Empagliflozin 25 mg 2323 2247 2221 2197 2169 2129 2102 2066 1878 1571 1351 1212 1070 842 528 216 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

Heart rate (ECG) Empagliflozin 10 mg Placebo Empagliflozin 25 mg 1245_0025final--01-1503--study-report-body (1). Table 15.3.3.2.3: 1 Heart rate (bpm) change from baseline MMRM results over time - treated set (OC-AD) 28 52 80 108 136 164 192 Placebo 2174 2127 2032 1928 1796 1300 1002 552 Empagliflozin 10 mg 2205 2137 2064 2006 1877 1366 1045 597 Empagliflozin 25 mg 2192 2127 2066 2006 1907 1383 1086 633 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

Low-density lipoprotein cholesterol Placebo Empagliflozin 25 mg Empagliflozin 10 mg 1245_0025final--01-1503--study-report-body (1). Table 15.3.2.4.3.3: 1 LDL cholesterol (mg/dL) change from baseline MMRM results over time − treated set (OC−AD) 4 28 52 80 108 136 164 192 Placebo 2297 2273 2179 2104 2006 1932 1419 1086 694 Empagliflozin 10 mg 2294 2269 2205 2143 2072 1998 1474 1133 740 Empagliflozin 25 mg 2287 2256 2188 2132 2060 2020 1503 1169 779 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements

High-density lipoprotein cholesterol Empagliflozin 25 mg Empagliflozin 10 mg Placebo 1245_0025final--01-1503--study-report-body (1). Table 15.3.2.4.2.3: 1 HDL cholesterol (mg/dL) change from baseline MMRM results over time − treated set (OC−AD) 4 28 52 80 108 136 164 192 Placebo 2297 2273 2181 2104 2007 1932 1419 1087 694 Empagliflozin 10 mg 2295 2270 2209 2144 2074 2001 1475 1134 741 Empagliflozin 25 mg 2289 2259 2191 2135 2064 2022 1507 1170 779 All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements